Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Liminal BioSciences Inc. (T:LMNL)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for LMNL within the last 6 months
See all filings within the past 6 months

Company News

Jan 13, 2020 06:00 ET
Liminal BioSciences Outlines Corporate Priorities for 2020
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Jan. 13, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ( "Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today provided a corporate update and outlined its key corporate and R&D priorities for 2020.
Read full article
Dec 23, 2019 14:43 ET
Liminal BioSciences Comments on Unusual Market Activity
LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, UK, Dec. 23, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ( "Liminal BioSciences" or the "Company"), is issuing this news release in light of unusual trading activity related to the common shares of the Company (the "Shares") on the Toronto Stock Exchange ("TSX") and Nasdaq. While Liminal BioSciences does not normally comment on market activity, Liminal BioSciences confirms that it is not aware of any undisclosed material change in the business, operations or affairs of Liminal BioSciences that would account for the recent in
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jan 15, 202028,0334,520
Dec 31, 201923,513-16,390
Dec 15, 201939,903-3,582
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Liminal BioSciences Inc., formerly Prometic Life Sciences Inc., is a Canada-based biopharmaceutical company. The Company is focused on developing a pipeline of small molecule therapeutics to treat patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. It operates through three segments: Small Molecule Therapeutics Segment, Plasma-derived Therapeutics Segment and Bioseparations segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Bioseparations segment is engaged in bioseparation, specifically for purification of biologics and the elimination of pathogens. Its product candidates include PBI-4050, PBI-4547, Ryplazim IV and Inter Alpha Inhibitor Protein (IAIP).

See business summary


Search (past week) for $LMNL.CA

  • No tweets found